Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab combinations in MSS metastatic colorectal cancer
NCT06513221Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jul 2024
- Primary completion
- Apr 2026
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of adebrelimab in metastatic colorectal cancer (mCRC), sponsored by Fudan University. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06513221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06513221.